Market Overview

UPDATE: Jefferies Lowers PT on Abbott Laboratories as Top US Pharma Pick

Share:
Related ABT
Earnings Beat Propels Abbott Laboratories To New All-Time High
Abbott Tops Q1 Expectations
Akorn Downgraded, Stock Falls On 'Credibility Gap' (Investor's Business Daily)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), but lowered the price target from $46.00 to $44.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Abbott Laboratories closed on Thursday at $36.30.

Latest Ratings for ABT

DateFirmActionFromTo
Apr 2015BarclaysMaintainsEqual-weight
Apr 2015JP MorganMaintainsNeutral
Mar 2015JefferiesMaintainsHold

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...